Kyntra Bio (NASDAQ:KYNB) Stock Moved Down to Strong Sell by Zacks Research

Zacks Research downgraded shares of Kyntra Bio (NASDAQ:KYNB) from a hold rating to a strong sell rating in a research note published on Monday,Zacks reports.

KYNB has been the subject of a number of other reports. Lake Street Capital assumed coverage on shares of Kyntra Bio in a research note on Thursday, September 17th. They set a “buy” rating and a $41.00 target price for the company. Weiss Ratings lowered shares of Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. Oppenheimer assumed coverage on shares of Kyntra Bio in a research report on Monday, July 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Maxim Group initiated coverage on shares of Kyntra Bio in a research report on Tuesday. They issued a “buy” rating and a $35.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $43.00 target price on shares of Kyntra Bio in a research note on Tuesday, September 1st. Five analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $36.80.

Kyntra Bio Stock Down 4.1%

KYNB stock opened at $5.87 on Monday. The business’s fifty day simple moving average is $7.26 and its two-hundred day simple moving average is $7.12. Kyntra Bio has a twelve month low of $5.62 and a twelve month high of $11.65. The firm has a market cap of $23.77 million, a price-to-earnings ratio of 0.13 and a beta of 1.05.

Hedge Funds Weigh In On Kyntra Bio

An institutional investor recently bought a new stake in Kyntra Bio stock. Renaissance Technologies LLC purchased a new stake in shares of Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned about 0.68% of Kyntra Bio as of its most recent filing with the Securities & Exchange Commission. 72.71% of the stock is owned by institutional investors and hedge funds.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.